ValiRx PLC Notice of GM (0779L)
September 28 2016 - 5:09AM
UK Regulatory
TIDMVAL
RNS Number : 0779L
ValiRx PLC
28 September 2016
VALIRX PLC
("ValiRx" or "the Company")
SHAREHOLDER CIRCULAR AND NOTICE OF GENERAL MEETING
London, UK, 28 September 2016: ValiRx Plc (AIM: VAL), a life
science company which focuses on clinical stage cancer therapeutic
development, taking proprietary & novel technology for
precision medicines towards commercialisation and partnering,
announces that it has recently published and posted to shareholders
a circular and notice convening a General Meeting of ValiRx Plc to
be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane,
London EC4A 1BN at 9:30 a.m. on 12th October 2016.
The directors will propose at the General Meeting shareholder
resolutions seeking shareholder authority to allot shares and the
dis-application of pre-emptive rights.
A copy of the Circular is available on the Company's website:
www.valirx.com
*** ENDS ***
For more information, please contact:
ValiRx Plc Tel: +44 (0) 20 3008
4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008
4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Tel: +44 (0) 7736
Manager 564 686
mark.treharne@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20 7148
(Nominated Adviser) 7900
Liam Murray / Jo Turner
Northland Capital Partners Tel: +44 (0) 203
Limited (Joint Broker) 861 6625
Patrick Claridge / David Hignell
(Corporate Finance)
John Howes / Abigail Wayne
(Broking)
Beaufort Securities Limited Tel: +44 (0) 207
(Joint Broker) 382 8300
Jon Belliss
Notes for Editors
ValiRx Plc
ValiRx is a biotechnology oncology focussed company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's three classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from Word class institutions, such
as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the Alternative Investment Market ("AIM")
of the London Stock Exchange in October 2006 and trades under the
ticker symbol: VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOGAKFDKKBKDFCB
(END) Dow Jones Newswires
September 28, 2016 06:09 ET (10:09 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024